Sökning: onr:"swepub:oai:gup.ub.gu.se/246736" >
Comorbidities, trea...
Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study.
-
Lesén, Eva (författare)
-
Granfeldt, Daniel (författare)
-
Houchard, Aude (författare)
-
visa fler...
-
Dinet, Jérôme (författare)
-
Berthon, Anthony (författare)
-
- Olsson, Daniel S, 1983 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
-
Björholt, Ingela (författare)
-
- Johannsson, Gudmundur, 1960 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition,Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
-
visa färre...
-
(creator_code:org_t)
- 2017
- 2017
- Engelska.
-
Ingår i: European journal of endocrinology. - 1479-683X. ; 176:2, s. 203-212
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Acromegaly is a complex endocrine disease with multiple comorbidities. Treatment to obtain biochemical remission includes surgery, medical therapy and radiation. We aimed to describe comorbidities, treatment patterns and cost-of-illness in patients with acromegaly in Sweden.A nationwide population-based study.Patients with acromegaly were identified and followed in national registers in Sweden. Longitudinal treatment patterns were assessed in patients diagnosed between July 2005 and December 2013. The cost-of-illness during 2013 was estimated from a societal perspective among patients diagnosed between 1987 and 2013.Among 358 patients with acromegaly (48% men, mean age at diagnosis 50.0 (s.d. 15.3) years) at least one comorbidity was reported in 81% (n=290). The most common comorbidities were hypertension (40%, n=142), neoplasms outside the pituitary (30%, n=109), hypopituitarism (22%, n=80) and diabetes mellitus (17%, n=61). Acromegaly treatment was initiated on average 3.7 (s.d. 6.9) months after diagnosis. Among the 301 treated patients, the most common first-line treatments were surgery (60%, n=180), somatostatin analogues (21%, n=64) and dopamine agonists (14%, n=41). After primary surgery, 24% (n=44) received somatostatin analogues. The annual per-patient cost was €12000; this was €8700 and €16000 if diagnosed before or after July 2005, respectively. The cost-of-illness for acromegaly and its comorbidities was 77% from direct costs and 23% from production loss.The prevalence of comorbidity is high in patients with acromegaly. The most common first-line treatment in acromegalic patients was surgery followed by somatostatin analogues. The annual per-patient cost of acromegaly and its comorbidities was €12000.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas